A Phase I, randomized, open-label, single-dose, three-period, three-sequence crossover study of Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Latest Information Update: 27 Feb 2025
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 23 Jul 2024 New trial record
- 15 Jun 2024 Results presented at the 25th Annual Congress of the European League Against Rheumatism